The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells
Open accessAbstract
Cancer progresses by evading the immune system. Elucidating diverse immune evasion strategies is a critical step in the search for next-generation immunotherapies for cancer. Here we report that cancer cells can hijack the mitochondria from immune cells via physical nanotubes. Mitochondria are essential for metabolism and activation of immune cells. By using field-emission scanning electron microscopy, fluorophore-tagged mitochondrial transfer tracing and metabolic quantification, we demonstrate that the nanotube-mediated transfer of mitochondria from immune cells to cancer cells metabolically empowers the cancer cells and depletes the immune cells. Inhibiting the nanotube assembly machinery significantly reduced mitochondrial transfer and prevented the depletion of immune cells. Combining a farnesyltransferase and geranylgeranyltransferase 1 inhibitor, namely, L-778123, which partially inhibited nanotube formation and mitochondrial transfer, with a programmed cell death protein 1 immune checkpoint inhibitor improved the antitumour outcomes in an aggressive immunocompetent breast cancer model. Nanotube-mediated mitochondrial hijacking can emerge as a novel target for developing next-generation immunotherapy agents for cancer. Cancer cells adopt a series of strategies to evade the immune response mounted by the organism against them. Here we find that tumour cells can hijack mitochondria from immune cells by forming physical nanotubes, and suggest that inhibiting this process might represent a potential immunotherapy approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Nanotubular Highways for Intercellular Organelle Transport
Rustom, A., Saffrich, R., Markovic, I., Walther, P., & Gerdes, H.-H. (2004) · Science · doi:10.1126/science.1093133 · Cited by 2,038
Vyas, S., Zaganjor, E., & Haigis, M. C. (2016) · Cell · doi:10.1016/j.cell.2016.07.002 · Cited by 1,735
Sena, L. A., Li, S., Jairaman, A., Prakriya, M., Ezponda, T., Hildeman, D. A., Wang, C.-R., Schumacker, P. T., Licht, J. D., Perlman, H., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.020 · Cited by 1,338
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 3×
“The animals were randomized into six treatment groups: (1) vehicle; (2) PD1 inhibitor (10 mg kg–1) alone; (3) L-778123 (40 mg kg–1) + PD1 inhibitor (10 mg kg–1); (4) L-778123 (80 mg kg–1) + PD1 inhibitor (10 mg kg–1); (5) L-778123 (120 mg kg–1) + PD1 inhibitor (10 mg kg–1); and (6) L-778123 (80 mg kg–1).”
BackgroundResultBrain tumour cells interconnect to a functional and resistant network
Osswald, M., Jung, E., Sahm, F., Solecki, G., Venkataramani, V., Blaes, J., Weil, S., Horstmann, H., Wiestler, B., Syed, M., et al. (2015) · Nature · doi:10.1038/nature16071 · Cited by 1,143
Sowinski, S., Jolly, C., Berninghausen, O., Purbhoo, M. A., Chauveau, A., Köhler, K., Oddos, S., Eissmann, P., Brodsky, F. M., Hopkins, C., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1682 · Cited by 754
Glater, E. E., Megeath, L. J., Stowers, R. S., & Schwarz, T. L. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200601067 · Cited by 666
Tseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 657
Cited by
The power and potential of mitochondria transfer
Borcherding, N., & Brestoff, J. R. (2023) · Nature · doi:10.1038/s41586-023-06537-z · Cited by 514
Immune evasion through mitochondrial transfer in the tumour microenvironment
Ikeda, H., Kawase, K., Nishi, T., Watanabe, T., Takenaga, K., Inozume, T., Ishino, T., Aki, S., Lin, J., Kawashima, S., et al. (2025) · Nature · doi:10.1038/s41586-024-08439-0 · Cited by 330
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease
Nguyen, T. T., Wei, S., Nguyen, T. H., Jo, Y., Zhang, Y., Park, W., Gariani, K., Oh, C.-M., Kim, H. H., Ha, K.-T., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01046-5 · Cited by 325
Mitochondrial degradation: Mitophagy and beyond
Uoselis, L., Nguyen, T. N., & Lazarou, M. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.08.021 · Cited by 270
Baldwin, J. G., Heuser-Loy, C., Saha, T., Schelker, R. C., Slavkovic-Lukic, D., Strieder, N., Hernandez-Lopez, I., Rana, N., Barden, M., Mastrogiovanni, F., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.029 · Cited by 253
Self-citation
Metadata
- Authors
- Saha, T., Dash, C., Jayabalan, R., Khiste, S., Kulkarni, A., Kurmi, K., Mondal, J., Majumder, P. K., Bardia, A., Jang, H. L., & Sengupta, S.
- Venue
- Nature Nanotechnology
- Published
- 2021-11-18
- Volume
- 17
- Issue
- 1
- Pages
- 98-106
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W3212198885
- Cited by
- 418
- References
- 34
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. https://app.cochat.ai/papers/10.1038/s41565-021-01000-4
- The paper
- Saha, T., Dash, C., Jayabalan, R., Khiste, S., Kulkarni, A., Kurmi, K., Mondal, J., Majumder, P. K., Bardia, A., Jang, H. L., & Sengupta, S. (2022). Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. Nature Nanotechnology. https://doi.org/10.1038/s41565-021-01000-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.